Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 11/20 | 0.48 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.47 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.47 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.47 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.43 |
| ▸ | CRACR2A | Q9BSW2 | 3/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | HTR1F | P30939 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16362102 | 0.97 | IL2 (0.48) | IL2STIM1ORAI1ORAI2MAP3K5 | |
| SCHEMBL16361892 | 0.94 | STIM1 (0.49) | IL2STIM1ORAI1ORAI2MAP3K5 | |
| SCHEMBL17697815 | 0.90 | CRACR2A (0.47) | IL2MAP3K5CRACR2A | |
| SCHEMBL17697817 | 0.89 | IL2 (0.46) | IL2MAP3K5PRKCQGPR55HTR1F | |
| SCHEMBL17697823 | 0.89 | IL2 (0.56) | IL2STIM1ORAI1ORAI2MAP3K5 | |
| SCHEMBL16362057 | 0.87 | IL2 (0.56) | IL2STIM1ORAI1ORAI2MAP3K5 | |
| SCHEMBL16362448 | 0.86 | IL2 (0.56) | IL2STIM1ORAI1ORAI2MAP3K5 | |
| SCHEMBL16362058 | 0.86 | IL2 (0.46) | IL2MAP3K5CRACR2AGPR55HTR1F | |
| SCHEMBL16362101 | 0.83 | IL2 (0.46) | IL2STIM1ORAI1ORAI2MAP3K5 | |
| SCHEMBL17697816 | 0.83 | IL2 (0.47) | IL2STIM1ORAI1MAP3K5CRACR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | claimed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | claimed |
| EP-3010586-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | Lupin Limited (IN) | 2016-04-27 | — | — | EP | claimed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725463-B2 | Substituted heterocyclic compounds as CRAC modulators | LUPIN LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145268-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS CRAC MODULATORS | RYR2, NR2C2, CACNA1E | IL2 2831/4885STIM1 303/4885ORAI1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.